Early Response to Imatinib Therapy in Chronic Myeloid Leukemia Patients in Côte d'Ivoire
Author Information
Author(s): Koffi Kouassi Gustave, Bognini Sara Akou, Silué Dohoma Alexis, Kamara Ismael, Kouakou Ines, N'dhatz Emeraude, Kouakou Boidy, Nanho Danho Clotaire, Okou David Tea
Primary Institution: Department of Hematology Teaching Hospital, Centre Hospitalier Universitaire de Yopougon, Ivory Coast
Hypothesis
The study aimed to evaluate the early molecular response to imatinib therapy and identify predictive factors for poor outcomes in chronic myeloid leukemia patients.
Conclusion
An early molecular response at 3 months can predict a deep molecular response in chronic myeloid leukemia patients treated with imatinib.
Supporting Evidence
- 48% of patients achieved an optimal response with TKI therapy after 3 months.
- 90% of patients with an optimal response at 3 months showed a deep molecular response.
- Seven independent risk factors were identified that significantly influenced early molecular response.
Takeaway
This study shows that checking how well patients respond to imatinib after 3 months can help doctors know if they will do well with the treatment.
Methodology
60 newly diagnosed CML patients were treated with imatinib and their early molecular response was assessed using RT-qPCR at 3 months.
Potential Biases
Potential biases may arise from the limited sample size and the specific demographic of the study population.
Limitations
The study was limited to a single center in Côte d'Ivoire and may not be generalizable to other populations.
Participant Demographics
The median age of participants was 45 years, with 57% male and 43% female.
Statistical Information
P-Value
0.00001
Confidence Interval
95% CI: 1.186–10.108
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website